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Male and female hypertrophic rat cardiac
myocyte functional responses to ischemic
stress and β-adrenergic challenge are
different
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Abstract
Background: Cardiac hypertrophy is the most potent cardiovascular risk factor after age, and relative mortality
risk linked with cardiac hypertrophy is greater in women. Ischemic heart disease is the most common form of
cardiovascular pathology for both men and women, yet significant differences in incidence and outcomes exist
between the sexes. Cardiac hypertrophy and ischemia are frequently occurring dual pathologies. Whether the
cellular (cardiomyocyte) mechanisms underlying myocardial damage differ in women and men remains to be
determined. In this study, utilizing an in vitro experimental approach, our goal was to examine the proposition
that responses of male/female cardiomyocytes to ischemic (and adrenergic) stress may be differentially modulated
by the presence of pre-existing cardiac hypertrophy.
Methods: We used a novel normotensive custom-derived hypertrophic heart rat (HHR; vs control strain normal
heart rat (NHR)). Cardiomyocyte morphologic and electromechanical functional studies were performed using
microfluorimetric techniques involving simulated ischemia/reperfusion protocols.
Results: HHR females exhibited pronounced cardiac/cardiomyocyte enlargement, equivalent to males. Under
basal conditions, a lower twitch amplitude in female myocytes was prominent in normal but not in hypertrophic
myocytes. The cardiomyocyte Ca2+ responses to β-adrenergic challenge differed in hypertrophic male and female
cardiomyocytes, with the accentuated response in males abrogated in females—even while contractile responses
were similar. In simulated ischemia, a marked and selective elevation of end-ischemia Ca2+ in normal female
myocytes was completely suppressed in hypertrophic female myocytes—even though all groups demonstrated
similar shifts in myocyte contractile performance. After 30 min of simulated reperfusion, the Ca2+ desensitization
characterizing the male response was distinctively absent in female cardiomyocytes.
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Conclusions: Our data demonstrate that cardiac hypertrophy produces dramatically different basal and
stress-induced pathophenotypes in female- and male-origin cardiomyocytes. The lower Ca2+ operational status
characteristic of female (vs male) cardiomyocytes comprising normal hearts is not exhibited by myocytes of
hypertrophic hearts. After ischemia/reperfusion, availability of activator Ca2+ is suppressed in female hypertrophic
myocytes, whereas sensitivity to Ca2+ is blunted in male hypertrophic myocytes. These findings demonstrate that
selective intervention strategies should be pursued to optimize post-ischemic electromechanical support for male
and female hypertrophic hearts.
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Background
For both women and men, cardiovascular disease is the
leading cause of death and disability [1, 2]. Cardiac
hypertrophy is the most potent cardiovascular risk factor
after age [3], and importantly, relative mortality risk
linked with cardiac hypertrophy is greater in women [4].
There is a growing clinical recognition that myocardial
cardiac stress responses, including neurohumoral activa-
tion, exhibit inherent sex difference [5].
Ischemic heart disease is the most common form of
cardiovascular pathology for men and women [6]. Ische-
mic events occur earlier in men, and ischemia-related
arrhythmia and sudden cardiac death incidence are
higher in men. In contrast, while younger women have a
lower risk of ischemic heart disease, in the event of a
myocardial infarct, they experience higher mortality and
rate of heart failure, even though reperfusion status is
equivalent [7, 8]. Women with ischemic heart disease
have higher rates of hospitalization than men [9]. The
essential question of whether the mechanisms under-
lying ischemic heart disease in women differ from men
remains unanswered [10]—and the cognate issue of
whether ischemia coincident with hypertrophic comor-
bidity has differing gender aetiology and outcome has
not been addressed.
The importance of achieving a more detailed under-
standing of basic mechanisms of sex difference in patho-
physiologic processes, which have particular relevance to
cardiovascular disease and health demography, has been
emphasized [11]. The value of sex-inclusive quality pre-
clinical data to inform large-scale clinical studies has
also been recently highlighted in the context of unex-
pected findings delivered by the RELAX trial—which
sildenafil (a phosphodiesterase 5 inhibitor) did not show
a beneficial effect in the treatment of heart failure with
preserved ejection fraction [12]. In retrospect, it became
apparent that this outcome might have been predicted if
the rationale for the trial had not been reliant on data
from male-only human and animal studies [13, 14].
Experimentally, important insights have been gained in
relation to sex-specific differentials in the impacts of car-
diac hypertrophy and of exposure to ischemic insult—yet
still, knowledge is lacking [15, 16]. The extent of hyper-
trophic remodeling in female rodents in response to
loading stress is generally attenuated, yet exogenous
oestrogen and oestrogen receptor (oestrogen receptor α
(ERα)) agonists have been shown to increase mortality
in mice subjected to aortic constriction or to infarction
[17–19]. Generally, female hearts are less susceptible to
post-ischemic contractile dysfunction, findings which
primarily derive from experiments involving animal
models where function is not compromised by pre-
existing pathologies [15, 20–22]. We have previously
established that the intrinsic resistance of isolated female
hearts to ischemic insult is abrogated in a setting of
primary cardiac hypertrophy [23].
Most fundamentally, protection against hypertrophy
and ischemia-driven arrhythmogenesis and contractile
dysfunction is determined by cardiomyocyte Ca2+ regu-
latory status. Whilst limited sex-specific information is
available at the myocyte level, in vitro findings suggest
differential female and male contractile/Ca2+ handling
characteristics in simulated ischemia and also sex diffe-
rences in the responsiveness of myocytes to manipu-
lation of adrenergic activation [24, 25]. Specifically, it is
reported that during simulated ischemia, only female
cardiomyocytes exhibit a reduction in Ca2+ transient
amplitude (vs non-ischemic control) and that in re-
perfusion, female cardiomyocytes are hyper-contractile
(vs males) and more likely to survive the ischemia/
reperfusion challenge [24]. Sex differences in adrener-
gic responses apparently reflect reduced cyclic adeno-
sine monophosphate (cAMP) levels in female myocytes
(vs male), contributing to lower Ca2+ levels and internal
Ca2+ store flux responses [25]. Importantly, no previous
cardiomyocyte functional studies have interrogated
the role of pre-existing hypertrophic pathology in
determining the sex-specific responses to ischemic
injury—a highly relevant clinical scenario of comor-
bidity [26, 27].
In this study, utilizing an in vitro experimental ap-
proach, our goal was to examine the proposition that
responses of male and female cardiomyocytes to stress
stimuli (β-adrenergic activation and simulated ischemia/
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reperfusion insult) may be differentially affected by the
presence of pre-existing cardiac hypertrophy. Using a
purpose-derived rat model of normotensive cardiac hyper-
trophy, the hypertrophic heart rat (HHR), a range of
cardiomyocyte morphologic and electromechanical func-
tional studies was performed using microfluorimetric
techniques. We have previously reported premature
mortality in the HHR (vs normal heart rat (NHR)),
with ex vivo HHR exhibiting normal systolic function
and an increased vulnerability to ischemia/reperfusion
dysfunction/injury [23, 28]. The present study now
demonstrates that cardiac hypertrophy produces dramat-
ically different pathophenotypes in female- and male-
origin cardiomyocytes exposed to ischemia. These findings




Animals were obtained from established colonies of the
HHR and the control NHR, maintained at the Biological
Research Facility at the University of Melbourne,
Australia, and derived as reported [29]. Briefly, these
rats originated from the F2 progeny of a cross between
the Fischer 344 and spontaneously hypertensive rat
(SHR). Normotensive offspring were selected for either
enlarged or normal heart size by echocardiography over
successive generations to achieve genetic stability. Tele-
metry, tail-cuff plethysmography and direct intra-arterial
recording methods have been used to determine the
normotensive status of these animals [29]. Experiments
were conducted and animals handled in the manner
specified by the NHMRC/CSIRO/ACC Australian Code
of Practice for the Care and Use of Animals for Scientific
Purposes (1997) and the EU Directive 2010/63/EU for
animal experiments, with approval and oversight by the
University of Melbourne Animal Ethics Committee.
Cardiomyocyte isolation procedure
Ventricular myocytes were isolated from NHR and HHR
rats, as described [30]. Briefly, animals were weighed,
killed by decapitation under deep halothane anaesthesia,
hearts were excised, trimmed, buffer washed and blotted
prior to taking weight measurement by tare. Hearts
were retrogradely perfused with bicarbonate-buffered
Ca2+-free Krebs (in millimolars: 118 NaCl, 4.8 KCl,
1.2 KH2PO4, 1.2 MgCl2, 25 NaHCO3, 11 D-glucose) at
73 mmHg for 3 min at 37 °C. Cardiomyocytes were then
perfused with type II collagenase (50 mg/ml, 295 U/mg;
Worthington Biochemical Corporation, NJ, USA) to
enable heart digestion. The heart was removed from the
cannula, and the ventricular cardiomyocytes dispersed in
Krebs/collagenase solution (in millimolars: 146.2 NaCl,
4.7 KCl, 0.4 NaH2PO4-H2O, 1.1 MgSO4-7H2O, 10 (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
11 D-glucose) supplemented with trypsin inhibitor
(25 μg/ml; Sigma-Aldrich, MO, USA) to inhibit residual
collagenase activity. For each heart, 100 rod-shaped and
regularly striated cardiomyocytes were selected at random
for length and width measurement at ×400 magnification
using an inverted light microscope and calibrated eye
piece as previously described [31]. Cardiomyocyte volume
was derived from the product of cell length and width,
multiplied by 7.59 × 10−3 pl/μm2 [32].
Cardiomyocyte Ca2+ handling and twitch analysis
Isolated myocyte Ca2+ levels and shortening perfor-
mance were measured [30]. Cell suspensions were incu-
bated with the Ca2+ fluorescent dye, fura2-AM (2.5 μM,
20 min, 25 °C; Invitrogen). Myocytes were superfused
with 2 mM Ca2+-HEPES buffer (in millimolars: 146.2
NaCl, 4.7 KCl, 0.4 NaH2PO4H2O, 1.1 MgSO47H2O, 10
HEPES, 11 glucose, pH 7.4) and stimulated to establish
steady state contractile performance at 4 Hz (5 min,
37 °C). Cardiomyocyte twitch properties were assessed by
video-based edge detection (IonOptix, MA, USA). The in-
dices used to describe twitch cycle were twitch amplitude
normalized to diastolic cell length (twitch amplitude per-
centage) and maximal rate of shortening and lengthening
(mrs and mrl, respectively; μm/s, normalized to diastolic
cell length). Myocyte Ca2+ signals were measured by
microfluorimetry (360:380 nm fluorescence ratio, 1000 Hz
sampling; IonOptix, MA, USA) [30]. Fluorescence signals
were corrected for background. The indices used to de-
scribe the Ca2+ transient were amplitude (F360:380) and the
time constant of decay (tau, ms; time constant measured
from curve fitted from 10 % below the peak level to
baseline of transient). Cardiomyocyte twitch and Ca2+
fluorescent ratio properties were measured off-line using
IonWizard (IonOptix) and were determined by average of
ten steady state transients for each myocyte. Ca2+-shorten-
ing phase loops were constructed for individual activation
cycles by plotting Ca2+ level vs myocyte shortening
throughout the shortening and lengthening phases of the
cycle. During the relaxation (i.e. lengthening) phase, the
Ca2+ level at half (50 %) relaxation may be interpreted as
an index of myofilament Ca2+ sensitivity [33].
Adrenergic challenge protocol
To assess the response of male and female NHR and
HHR cardiomyocytes to an adrenergic challenge, myo-
cytes stabilized for 5 min in 2 mM Ca2+-HEPES buffer
were superfused with 10 nM isoproterenol for 5 min.
Previous dose range and time-course studies confirmed
this was an optimal time point to allow a maximal shor-
tening and amplitude Ca2+ response to reach a new
steady state [34].
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Simulated ischemia/reperfusion protocol
To assess the response of male and female NHR and
HHR cardiomyocytes to an ischemia and reperfusion
challenge, cardiomyocytes were superfused with a modi-
fied HEPES buffer (in millimolars: 136 NaCl, 8 KCl, 0.4
NaH2PO4-H2O, 1.1 MgSO4-7H2O, 2.0 CaCl2, 10 HEPES,
10 lactate, pH 6.8, 100 % N2 gas saturation) for 20 min
to simulate conditions associated with ischemia, inclu-
ding hypoxia, hypercapnia, acidosis, substrate deprivation
and lactate accumulation [30, 35, 36]. At the end of
the 20-min superfusion with the simulated ischemia
solution, the perfusate was switched back to the basal
2-mM Ca2+-HEPES buffer for a further 30 min. Car-
diomyocytes were electrically stimulated (4 Hz) through-
out the ischemia/reperfusion protocol.
Statistics
Data are presented as mean ± SEM. Differences between
groups were assessed by two-way ANOVA and with
repeated measures as appropriate. Myocyte survival
curves were assessed by log-rank Mantel-Cox test. Data
were considered significant at p < 0.05. All statistical
calculations were performed using SPSS V.22.0 (IBM
Corp, NY, USA). Statistical annotation used throughout
the study to designate significance level: #, strain effect; *,
sex effect; †, sex-strain interaction. Post hoc analysis
was performed on data in which a sex-strain interaction
was evident, with significant differences in post hoc
analysis represented in the figures (§, p < 0.05, male vs
female of same strain) directly above the relevant figure
bar or data point.
Results
Cardiac and cardiomyocyte hypertrophy in male and
female HHR
Female body and heart weights were significantly
lower than strain and age-matched NHR and HHR
values (Table 1). Heart weight and cardiomyocyte
dimensions were smaller in female NHR (Table 1 and
Fig. 1, respectively), yet cardiac weight index (CWI;
g/kg) was greater compared with male NHR. In HHR,
cardiac and cardiomyocyte hypertrophy was most pro-
nounced in female with augmented CWI associated
with more substantial myocyte enlargement in width
(and consequently volume) dimension (Table 1 and
Fig. 1, †p < 0.05; Fig. 1b–d). These data confirm a robust
hypertrophic phenotype in female and male HHR.
Cardiomyocyte basal performance—sex differences
suppressed with hypertrophy
Basal NHR cardiomyocyte contractile performance was
lower in female cardiomyocytes compared with males
(Fig. 2a–d, Additional file 1: Table S1 *p < 0.05). This
lower female contractility was marked in normal female
myocytes (approximately 50 % lower of the percentage
shortening values vs male NHR), though time to peak
shortening was particularly slow in female HHR cardio-
myocytes (Additional file 1: Table S1). Lower contrac-
tility in normal female myocytes was associated with a
trend for lower Ca2+ transient amplitude and systolic
Ca2+ (Fig. 2e, f, Additional file 1: Table S1). No sex
difference was observed in NHR cardiomyocyte diastolic
Ca2+ levels or the time constant of Ca2+ transient decay
(Fig. 2g, h). Lower contractility was not apparent in
female HHR cardiomyocytes relative to male (Fig. 2b).
As for NHR, overall Ca2+ levels did not differ between
male and female HHR myocytes (Fig. 2e–h). These
data show that basal contractile performance in non-
hypertrophic male and female cardiomyocytes is fun-
damentally different, but this sex differential is lost
when myocytes exhibit pathological hypertrophy.
Augmented HHR Ca2+ activator response to
β-adrenoceptor stimulation in male cardiomyocytes
absent in female cardiomyocytes
β-Adrenoceptor agonist challenge in vitro elicited a
substantial increase in cardiomyocyte contractility (Fig. 3a,
Additional file 2: Table S2). The magnitude of this
response was similar in male and female cardiomyocytes,
but more pronounced in the presence of hypertrophy
(Fig. 3b–d, M NHR 178.9 ± 16.1 %, F NHR 213.5 ± 32.1 %,
M HHR 282.9 ± 36.3 %, F NHR 300.7 ± 25.2 %, #p < 0.05).
Sex differences in the Ca2+ response to β-adrenoceptor
stimulation were evident. The extent of isoproterenol-
induced increase in Ca2+ transient amplitude was select-
ively blunted in female HHR myocytes compared with
males (Fig. 3e, †p < 0.05). This sex-specific response was
not observed in non-hypertrophic (NHR) myocytes.
Table 1 Age and body/heart weights of male and female NHR and HHR
Parameter NHR HHR
Male Female Male Female
Age (weeks) 14.6 ± 0.7 (15) 13.3 ± 0.3 (13) 14.8 ± 1.0 (14) 13.7 ± 0.6 (13)
Body weight (g) 352 ± 7.9 (15) 180 ± 5.5# (13) 299 ± 10.2## (14) 171 ± 4.7## (13)
Heart weight (mg) 1410 ± 28.5 (15) 882 ± 27.7# (13) 1514 ± 85.8 (14) 1202 ± 69.2#,## (13)
CWI (mg/g) 4.02 ± 0.1 (15) 4.91 ± 0.1# (13) 5.12 ± 0.3## (14) 7.04 ± 0.4#, ## (13)
#sex p < 0.05; ##strain p < 0.05, mean ± SEM, n = hearts or animals in brackets for each group
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Diastolic Ca2+ levels were stable with isoproterenol
challenge in all treatment groups (Fig. 3f). A more rapid
transient decay (decrease in tau) was evident in hyper-
trophic male and female cardiomyocytes, consistent with
a trend for increased maximum rate of lengthening
(Fig. 3d, g). These data demonstrate that the Ca2+
response to β-adrenergic stimulation is different in male
and female hypertrophic cardiomyocytes—the accentuated
response in HHR male myocytes is not achieved in female
myocytes.
Selective Ca2+ elevation in female myocytes at end
ischemia abrogated with hypertrophy
Myocyte contractile performance and Ca2+ levels were
tracked throughout the time-course of a simulated
ischemia/reperfusion challenge (sample time-compressed
Fig. 1 Cardiomyocyte hypertrophy in male and female HHR. a Representative images of cardiomyocytes from male and female NHR and HHR
hearts. b–d Augmented CWI associated with more substantial myocyte enlargement in width (and consequently volume) dimension in female
vs male HHR (*sex p < 0.05; #strain p < 0.05; †sex-strain interaction; §post hoc male vs female p < 0.05, mean ± SEM. Each data point mean of
n = 50 cells from each of eight hearts/group, total 400 cells/gp)
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record, Fig. 4a, Additional file 2: Table S2). At the
commencement of ischemia, all cell groups demon-
strated an abrupt decrease in twitch amplitude and a
small increase in resting length. This reduction in
twitch amplitude reached a plateau within the first
5 min of simulated ischemia (Fig. 4b), with no signifi-
cant difference between groups in the extent of twitch
amplitude reduction at end ischemia (Fig. 4c). Ca2+
transient responses to simulated ischemia were very differ-
ent in male and female cardiomyocytes (Fig. 4d, †p < 0.05).
In contrast to males, female NHR cardiomyocytes exhib-
ited a substantial increase in amplitude Ca2+ at the end of
ischemia (relative to pre-ischemic basal; M NHR 104.8 ±
13.3 %, F NHR 186.2 ± 35.9 %, *p < 0.05), which was not
associated with a concomitant increase in shortening
(Fig. 4e). This marked and selective elevation of end-
ischemia Ca2+ in female NHR was totally abrogated with
hypertrophy (HHR, Fig. 4e, M HHR 73.1 ± 9.5, F HHR
66.8 ± 10.9 %). Despite a significantly lower Ca2+ signal in
hypertrophic cardiomyocytes (Fig. 4e, #p < 0.05), the
Fig. 2 Basal sex differences in cardiomyocyte performance suppressed with hypertrophy. a Representative records of myocyte shortening in
male and female NHR and HHR cardiomyocytes. b–d Basal twitch amplitude (% shortening), maximum rate of shortening/lengthening are lower
in female cardiomyocytes compared with males—an effect that is accentuated in NHR compared with HHR. e No sex difference was observed
in Ca2+ transients, though a trend for lower Ca2+ transient amplitude was evident in female NHR cardiomyocytes (f). No sex difference was
observed in cardiomyocyte diastolic Ca2+ levels or the time constant of Ca2+ transient decay (g, h). (*sex p < 0.05; p < 0.05; mean ± SEM; n = 8–13
cells from four to five hearts/group)
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Fig. 3 β-Adrenoceptor stimulation Ca2+response blunted in hypertrophic female HHR cardiomyocytes. a Representative cardiomyocyte shortening
trace (central portion time compressed) showing isoproterenol (10 nM) exposure-elicited response of rapid and sustained increase in cell twitch.
b–d The extent of increase in shortening and maximum rate of shortening was similar in male and female cardiomyocytes, but more pronounced
in the presence of pathological hypertrophy. Rate of lengthening was unchanged. e The extent of isoproterenol-induced increase in Ca2+ transient
amplitude was selectively blunted in female HHR myocytes. f Diastolic Ca2+ levels were stable with isoproterenol challenge in all treatment groups,
whilst tau (g) was significantly faster in HHR of both sexes (#strain p < 0.05; †sex-strain interaction; §post hoc male vs female p < 0.05, mean ± SEM,
n = 9–11 cells from four to five hearts/group)
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Fig. 4 (See legend on next page.)
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shortening responses between male and female HHR were
not different (Fig. 4c, p = ns). A sex-strain interaction was
evident for diastolic Ca2+ during simulated ischemia
(Fig. 4f, g). An increase in diastolic Ca2+ in male HHR
cardiomyocytes was not evident in female HHR, which
remained at near-basal levels of diastolic Ca2+ (Fig. 4g).
This contrasted with NHR myocytes, with a trend for
greater diastolic Ca2+ at the end of simulated ischemia
compared with males.
Myofilament Ca2+ desensitization in reperfused
hypertrophic male myocytes is absent in females
During the simulated reperfusion phase of the protocol,
myocytes of all groups most typically exhibited a rapid
decrease in resting length (i.e. a diastolic contracture
response) with decrement in twitch amplitude, followed
by gradual return to a new steady state in the extent of
myocyte shortening, albeit diastolic relaxation state was
only partially regained (Fig. 4a). Myocyte attrition (acute
necrosis/oncosis) was observed throughout both the
ischemic and reperfusions phases of the protocol (Fig. 5a).
In males, there was a trend for hypertrophic myocytes
(HHR) to be more resistant to cell death during the
simulated ischemia/reperfusion challenge compared with
normal myocytes (NHR), though this did not reach
significance (Fig. 5a). A strain trend was not apparent in
female myocytes. All groups showed full recovery from
ischemic diastolic contracture, with resting cardiomyocyte
length lower at end reperfusion compared with the pre-
ischemic basal level (Fig. 5b). The extent of this reduction
was greatest in male NHR cardiomyocytes and signifi-
cantly greater than in female NHR cardiomyocytes. This
sex difference was not apparent when cardiomyocytes
were hypertrophic. During the first 5 min of reperfusion,
spontaneous contractions were evident in male NHR (one
of eight cardiomyocytes) and HHR (four of nine cardio-
myocytes) cardiomyocytes, contrasting with a lack of
spontaneous contractions in both female NHR and HHR
cardiomyocytes, At the end of the 30-min simulated
reperfusion challenge, surviving male and female cardio-
myocytes from normal and hypertrophic hearts exhibited
very different recovery parameters (Fig. 5c, †p < 0.05).
Male HHR cardiomyocytes demonstrated equivalent
shortening to male NHR controls, yet amplitude Ca2+ was
significantly increased. This directly contrasted with fe-
male HHR cardiomyocytes, where shortening was signi-
ficantly increased compared with female NHR controls,
yet amplitude Ca2+ was not different. Phase loop analyses
were performed to assess individual myocyte Ca2+-short-
ening relationships (Fig. 5d). Male, but not female, HHR
cardiomyocytes exhibited a large decrease in myofilament
Ca2+ sensitivity, with an approximate two- to threefold
increase in Ca2+ levels at 50 % myocyte relaxation
compared with male NHR and female NHR and HHR
cardiomyocytes (Fig. 5e, †p < 0.05). These data demon-
strate that, in contrast to hypertrophic male myocytes,
myofilament Ca2+ responsiveness in hypertrophic female
cardiomyocytes was not characterized by ‘desensitization’.
Thus, a major sex-specific stress response phenotype
difference emerges between female and male hypertrophic
cardiomyocytes when subjected to simulated ischemia
and reperfusion challenge.
Discussion
This investigation provides new evidence that male and
female hearts with an underlying pathological hyper-
trophy respond differently to cellular stresses. Using the
novel HHR model (a model of normotensive intrinsic
hypertrophy derived through a multigenerational pro-
gram of selective breeding), our findings document
pronounced cardiac and cardiomyocyte enlargement in
females—including cardiomyocyte dimensional increase
in female HHR equivalent to male HHR. Under basal
conditions, a lower twitch amplitude in female myocytes
was prominent in normal (NHR) but not in hypertrophic
(HHR) myocytes. The cardiomyocyte Ca2+ responses to
β-adrenergic challenge differed in hypertrophic male and
female cardiomyocytes, with the accentuated response in
males abrogated in females—even while contractile
responses were similar. In simulated ischemia, the Ca2+
transient responses of hypertrophic male and female
myocytes were markedly different—though again, all
groups demonstrated similar shifts in myocyte contrac-
tile performance. A prominent and selective elevation of
end-ischemia Ca2+ in female NHR was completely
suppressed in female hypertrophic myocytes. Similarly,
after the 30-min simulated reperfusion, male and female
cardiomyocytes evinced different Ca2+ response patterns
(See figure on previous page.)
Fig. 4 Selective Ca2+ elevation in female myocytes at end ischemia is abrogated with hypertrophy. a Representative cardiomyocyte shortening record
shows modulated diastolic length and twitch amplitude in simulated ischemia and reperfusion (time compressed). b All groups show a similar pattern
of shortening response to simulated ischemia. c No significant difference between groups was detected in the extent of change in twitch reduction at
end ischemia. d Ca2+ transient responses during the time-course of simulated ischemia. e Female NHR cardiomyocytes exhibited a substantial increase
in amplitude Ca2+ at the end of ischemia which was not evident in female hypertrophic myocytes. f Diastolic Ca2+ increased throughout ischemia in
male HHR cardiomyoctes. g At end ischemia, increased diastolic Ca2+ in male HHR was absent in female HHR myocytes. (*sex p < 0.05; #strain p < 0.05;
†sex-strain interaction; §post hoc male vs female p < 0.05; mean ± SEM; n = 7–14 cells from 6 to 11 hearts/group)
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indicating an absence of the Ca2+ desensitization charac-
terizing the male response.
Our data demonstrate that cardiac hypertrophy pro-
duces dramatically different basal and stress-induced
pathophenotypes in female- and male-origin cardiomyo-
cytes. The lower Ca2+ operational status characteristic of
female (vs male) cardiomyocytes comprising normal
hearts is not exhibited by myocytes of hypertrophic
hearts. After ischemia/reperfusion, availability of activa-
tor Ca2+ is suppressed in female hypertrophic myocytes,
whereas sensitivity to Ca2+ is blunted in male hyper-
trophic myocytes. These findings demonstrate that selec-
tive intervention strategies should be pursued to optimize
post-ischemic electromechanical support for male and
female hypertrophic hearts.
Normal female-male cardiomyocyte contractile
performance differential is eliminated with
concomitant hypertrophy
The present study assessed male/female cardiomyocyte
function and stress responses in a novel pathological
hypertrophic HHR strain (vs control NHR strain).
Significantly lower body weight in female rats is consis-
tent with previous reports [23, 37–39], as are our
findings that cardiomyocyte dimensions are smaller in
normal females (vs male NHR) [24, 40–42]. This male/
female cell size difference is not always evident and may
be dependent on animal strain, aging/disease context
and the experimental conditions under which myocyte
dimensions are measured (e.g. resting Ca2+ concentra-
tion) [37, 43]. The possibility that there is a fundamental
Fig. 5 Myofilament Ca2+ desensitization in hypertrophic male myocytes at the end of reperfusion is absent in females. a Cardiomyocyte survival
plots throughout simulated ischemia and reperfusion. b Resting myocyte length decreased to a greater extent in male NHR cardiomyocytes
compared with females, with this sex difference absent in the HHR. c At end reperfusion, male HHR cardiomyocytes maintain contractility yet
exhibit significantly increased Ca2+. Female HHR myocytes show augmented contractility with substantially lower transient Ca2+. d Phase loop
analysis shows male, but not female, HHR cardiomyocytes exhibit a modified Ca2+-shortening relationship. e Male HHR cardiomyocytes exhibit
significantly lower level of myofilament Ca2+ sensitivity, with an approximate two to threefold increase in Ca2+ levels at 50 % myocyte relaxation.
(*sex p < 0.05; #strain p < 0.05; †sex-strain interaction; §post hoc male vs female p < 0.05; mean ± SEM; n = 5–8 cells from four to six hearts/group)
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relationship between cardiomyocyte size and electro-
mechanical characteristics which may partly reflect a
sex-dependent size-scaling effect merits future investi-
gation. The present finding that under standardized
basal conditions, normal female cardiomyocytes con-
tract at a lower operating level than male myocytes is
consistent with our earlier report (subsequently confirmed
by others) [16, 39]. This feature of female cardiomyocyte
performance suggests a relatively ‘economical’ basal meta-
bolic state. There are discrepancies within the literature
regarding the mechanisms driving this female phenotype,
though changes in Ca2+ transporter function are undoub-
tedly implicated. While differences in protein expression
levels of various Ca2+ transporters have been reported
between males and females in some contexts [15, 30],
oestrogen regulation of the activity of some key Ca2+
handling effectors is likely to be of most functional
importance [15, 44–48]. These previous studies assessing
Ca2+ transporter expression/activity have utilized a series
of different species (e.g. mouse, rat, guinea pig) and
animal ages, which may explain variability in findings. We
have recently shown that expression of the sarcoplasmic
reticulum (SR) Ca2+ release channel (RyR2) does not
differ in male/female Sprague Dawley (SpD) rats (12–
16 weeks) [30], similar to that reported in 5–10-
month-old C57Bl/6 mice [25]. This contrasts to previous
studies in SpD and Wistar rats (age not stated), reporting
an increased expression of the SR Ca2+ release channel
(RyR2) [49, 50]. We also showed no difference in sarco-
plasmic/endoplasmic reticulum Ca2+ ATPase (SERCA2a)
and phospholamban (PLB) expression in male/female SpD
rats, consistent with previous reports [49]. Directly rele-
vant to the present study, we have shown that expression
of RyR2, SERCA2a and PLB was not different in female
HHR and NHR ventricular homogenates [30]. Our data
indicate that it is the regulation of Ca2+ transporter acti-
vity, and not the expression, that differs in males/females.
In particular, we have shown that basal Ca2+/calmodulin-
dependent kinase II (CaMKII) phosphorylation (and
hence, CaMKII-mediated phosphorylation of RyR2 and
PLB) is lower in females, a mediator which exerts major
influence on numerous Ca2+ transporter properties [30].
Estrogenic influence on cardiomyocyte Ca2+ hand-
ling includes voltage-gated Ca2+ current suppression,
internal Ca2+ store release modulation and myofila-
ment Ca2+ sensitivity alteration [25, 46, 51–59]. The
sex-specific distinguishing characteristics in contractile
phenotypes in non-hypertrophic myocytes can be par-
tially attributed to a Ca2+-dependent mechanism, but
likely non-Ca2+ dependent estrogenic actions (cell ener-
getics/gene expression) are involved [5, 60] as the extent
of contractility performance difference between males and
females was more prominent than the Ca2+ transient
amplitude differences.
Hypertrophy is linked with accentuated response to
β-adrenoceptor stimulation in male, but not female
myocytes
Sex-specific aspects of altered β-adrenoceptor response
in cardiac disease pathogenesis are not well cha-
racterized. Experimentally, evidence indicates that the
β-adrenergic response is less pronounced in healthy
cardiac tissues/myocytes of females compared with males
under some circumstances. We and others have previ-
ously shown that Ca2+ transients are smaller in female
cardiomyocytes (vs males) treated with isoproterenol
[39, 61–63]. These male/female differences do not appear
due to changes in β-adrenergic expression/density
[64, 65], and suppressed responsiveness in females is
more likely attributable to downstream signaling interme-
diates (i.e. adenylyl cyclase/PKA/cAMP) [25, 62].
We did not observe male/female differences in the
extent of increase in twitch or Ca2+ transient amplitude
in isoproterenol-treated NHR myocytes—suggesting that
pacing under near-physiological conditions minimizes
response difference [65]. Notably, male/female differ-
ences in response to isoproterenol were evident in
hypertrophic myocytes. Hypertrophic female myocytes
did not exhibit the accentuated elevation in Ca2+ transi-
ent amplitude observed in male HHR myocytes, even
though both female and male HHR had similarly aug-
mented contractile responses. This suggests a Ca2+-inde-
pendent component determining adrenergic response
selectively in females. The mechanism is unclear, but
may be related to differential cellular metabolism
profile—with hypertrophic hearts drawing on sex-
selective energy reserves to effect an adrenergic-driven
contractile response [5, 66].
Cardiomyocyte Ca2+ handling and responsiveness during
ischemia and reperfusion is different in hypertrophy in
females and males
In this investigation, distinct mechanisms underlying
vulnerability to ischemia/reperfusion in female- and
male-origin cardiomyocytes are identified. These find-
ings build on our prior observations involving isolated
ex vivo hearts where we established that the more
robust functional recovery of female hearts to ische-
mic insult was abrogated in hypertrophy [23]. In that
study, HHR male and female hearts performed equally
poorly, displayed similar necrotic damage (lactate
dehydrogenase release) and the enhanced activation of
the pro-survival reperfusion injury survival kinase
(RISK; [23]) pathway seen in NHR female hearts was
absent in HHR female hearts. In the two heart strains,
coronary flow during ischemia/reperfusion in that study
was also not different—eliminating vascular perfusion
status as an underlying causative agent in sex- and strain-
related performance. Our new in vitro finding presented
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in this investigation, that overall isolated cardiomyocyte
viability loss through simulated ischemia/reperfusion was
not different between sexes or strains, indicates that the
measures of ex vivo heart damage reflect primarily cell
rupture injury attributable to in situ tissue torsion (likely
during contracture) and not cell-origin oncotic lesion.
During ischemia, female NHR showed a surprising
tolerance for elevated cardiomyocyte Ca2+ levels—sug-
gesting that the interplay between Ca2+, Na+ and pH
which is an important determinant of electromechanical
status at end reperfusion operates differently in normal
male and female myocytes. Related, but qualitatively
different, observations have been previously reported.
The sex differences in ionic homeostatic responses to
simulated ischemia may depend on precise experimental
conditions [24]. Sex-comparative data relating to hyper-
trophic cardiomyocytes have not previously been pre-
sented. An exploration of how these ionic flux responses
may be differentially manipulated via pharmacologic
means may provide a valuable therapeutic lead for new
post-ischemia sex- and disease-specific intervention
approaches.
Cell shortening is typically reduced by approximately
50 % relative to basal in the first 5 min of simulated
ischemia, though this reduction was attenuated in female
HHR cardiomyocytes (Fig. 4a). This 50 % reduction is
similar to that described previously [24, 67], though not
as extensive as other studies describing near cessation of
myocyte shortening [35, 36, 68–70]. As was observed in
isolated HHR hearts [23], at the end of ischemia, male
and female isolated cells showed similar levels of con-
tractile recovery (whereas in NHR sex-specific perfor-
mance, differences were apparent). Most dramatically,
different underlying Ca2+ handling and response charac-
teristic produced this similar net effect in HHR cell
types. In the male HHR myocytes, a significant elevation
of Ca2+ transient amplitude occurred with a major
offsetting reduction in myofilament sensitivity to Ca2+.
In the female HHR myocytes, this combination of Ca2+
adaptations was not apparent. In relation to adverse
outcomes in early reperfusion, these findings may be
extrapolated to suggest that in acute reperfusion, Ca2+
overload arrhythmogenic predisposition presents as a
male myocyte vulnerability. In contrast, the blunted fe-
male myocyte Ca2+ transient response to β-adrenoceptor
inotropic influence has the potential for compromised
functional performance. Thus, ischemic recovery is simi-
larly impaired in both males and females—but via diffe-
rent cellular mechanisms. Clinically, the importance of
gender differences in arrhythmia substrate is increasingly
recognized—and advancing the understanding of under-
lying cellular processes involved is essential [71].
The present study, of young adult rodents at prime
estrogenic life stage, demonstrates the absence of a
female ‘protected’ state in the context of hypertrophy.
The conventional view of female oestrogen cardioprotec-
tion may require refinement [15, 72]. Oestrogen recep-
tors (ERα, oestrogen receptor β (ERβ), G-protein-
coupled oestrogen receptor (GPER)) are expressed in
male and female myocardium. When expression/activity
is manipulated genetically or pharmacologically, dual sex
effects may be observed [73]—yet oestrogen exposure is
not always favourable [15]. Experimentally, where female
hearts have shown more ischemic resilience than male
hearts, this has been most evident when the context
involved baseline elevated Ca2+ loading levels [20–22].
New information suggests that local myocardial
androgen-to-oestrogen conversion may be an element in
determining the sex specificity of responses to cardiac
challenge [74–76], and in hypertrophy, local steroid
levels may become more important in modulating func-
tion under stress conditions. More detailed studies of
the specific molecular processes involved in regulating
ionic homeostasis in male- and female-origin cardio-
myocytes in defined disease hypertrophic states and
acute stress settings are warranted. A limitation of the
present study is the in vitro and ‘unloaded’ conditions
under which myocyte recordings are undertaken. How-
ever, the advantage of the approach is the capacity to
achieve a high level of control over cellular ambience to
resolve key functional differences.
Conclusions
In summary, this experimental investigation demonstrates
that the responses of hypertrophic male and female car-
diomyocytes to β-adrenoceptor stimulation and ischemia/
reperfusion challenges are fundamentally different at the
cellular level—and that hypertrophy in females confers a
distinctive liability. Our findings indicate that therapeutic
interventions targeted to the early reperfusion period may
have differential sex-specific efficacy depending on the
presence of an underlying comorbid hypertrophic state.
Where clinical trials have previously failed to identify
benefit in early reperfusion manipulation of cellular pro-
cesses impacting on myofilament Ca2+ sensitivity, there
may be a case for review in selected at-risk female
subgroups. This study provides a basis to support relevant
focused pre-clinical research to pursue this possibility.
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